None listed
Conditions
Brief summary
The purpose of this study is to determine the presence of methylene tetrahydrofolate reductase (MTHFR) genetic polymorphisms in platinum resistance and platinum sensitive ovarian cancer patients. Who is it for? You may be eligible for this study if you are an adult who has been diagnosed with ovarian, fallopian tube, epithelial or peritoneal cancer. Study details: Participants will be asked to undertake a single blood test and complete the food frequency questionnaire designed by the Cancer Council Victoria. A single interview will also be conducted in order to record a thorough medical and family history, that will take approximately 1 hour. Participants will also be asked to consent to the use of their medical records for information regarding diagnosis and medical history. The project is aimed at providing an insight into the influence of diet in platinum responsiveness in ovarian cancer, and whether MTHFR status can be used as a prognostic biomarker for clinical decisions regarding treatment strategy, for patients at risk of platinum drug toxicity or poor responsiveness.
Interventions
The project is aimed at assessing MTHFR polymorphism prevalence in platinum resistance versus platinum sensitive ovarian cancer patients. Participants will be allocated into platinum resistant/refractory or platinum sensitive groups based on their clinical diagnosis by their treating oncologist following first line platinum drug therapy. Secondary assessment of folate dietary intake through natural and synthetic sources will be conducted using a food frequency questionnaire developed by the Canc
The project is aimed at assessing MTHFR polymorphism prevalence in platinum resistance versus platinum sensitive ovarian cancer patients. Participants will be allocated into platinum resistant/refractory or platinum sensitive groups based on their clinical diagnosis by their treating oncologist following first line platinum drug therapy. Secondary assessment of folate dietary intake through natural and synthetic sources will be conducted using a food frequency questionnaire developed by the Cancer Council Victoria based on the previous 12 months, analysing overall differences in intake between the groups, as well as differences between intake prior to and after diagnosis. Both primary and secondary observations will be used to identify any association between genetic or nutrigenomic influence in platinum drug response in ovarian cancer patients. A single interview will be conducted to collect a thorough medical and family history that will take approximately 1 hour. Participants will also be asked to consent to the use of their medical records for information regarding diagnosis and medical history.
Sponsors
Endeavour College of Natural Health
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
• Diagnosed with ovarian, fallopian tube, epithelial or peritoneal cancer • Completed first line platinum therapy • Diagnosed with refractory/resistant disease or platinum sensitive disease a minimum of 6 months after platinum therapy
Exclusion criteria
• Non-English speaking • Never received a platinum drug for ovarian cancer diagnosis
Outcome results
None listed